including 24 (6.1%) new genital herpes diagnoses. A similar pro-portion of patients developed STIs in the 1996–2004 group (19.8%)compared to the 2005–2012 group (20.7%), however the burden ofSTIs was greater in the latter group since these diagnoses occurredduring a shorter period of follow-up (median 2.8 years, IQR 1.3–5.2vs. 10.3 years, IQR 8.4–12.6; P < 0.01).Follow-up HSV serologic testing occurred at a median inter-val of 13.3 months (IQR 12.0–22.0 months) and 15.6 months (IQR13.2–26.5 months) for the 1996–2004 and 2005–2012 groups,respectively (P < 0.01). HSV-2 seroconversion occurred in 33 of 253(13.0%) patients after a median of 2.6 years after HIV diagnosiswith an incidence rate of 5.07 cases per 100 person years (95%CI 4.76–5.37). Of these, 4 of 67 HSV-2 negative patients seroconverted in the 1996–2004 group (6.0%) and 29 of 186 (15.6%) in the 2005–2012 group (P = 0.09). Of the 144 total patients seropositivefor HSV-2, 27 (18.8%) had a clinical history of genital herpes byICD-9 codes.